Critically ill patients exhibit a range of organ dysfunctions and often require treatment with a
variety of drugs including sedatives, analgesics, neuromuscular blockers, antimicrobials …

The pathophysiology of sepsis alters drug pharmacokinetics, resulting in inadequate drug
exposure and target-site concentration. Suboptimal exposure leads to treatment failure and …

Piperacillin–tazobactam is a β-lactam/β-lactamase inhibitor combination with a broad
spectrum of antibacterial activity that includes Gram-positive and-negative aerobic and …

Objectives: We investigated the population pharmacokinetics and pharmacodynamics of
piperacillin and tazobactam in hospitalized patients. Patients and methods: A multicentre …

Piperacillin-tazobactam is a potent β-lactam/β-lactamase inhibitor antibiotic commonly
prescribed in the intensive care unit setting. Admitted patients often show large variability in …

Importance of the field: Piperacillin-tazobactam is a frequently prescribed intravenous
antibiotic for moderate to severe infections used in hospital settings because of its broad …

Carbapenems are recommended for the treatment of urosepsis caused by extended-
spectrum β-lactamase (ESBL)-producing, multidrug-resistant Escherichia coli; however, due …

This study examined the effect of various levels of renal impairment on the probability of
achieving free drug concentrations that exceed the MIC for 50% of the dosing interval (50% f …

Here we describe the pharmacokinetics of piperacillin administered by continuous infusion
(CI) versus intermittent bolus (IB) dosing in critically ill patients receiving continuous …

Objective: Kinetics of piperacillin (pip), in combination with the beta-lactamase inhibitor
tazobactam (taz) have been studied in volunteers and patients in relatively stable conditions …